On this episode we feature the CEO of Bionyra, Frederic Marrache, after closing French-biotech’s larges ever Series A ($165million) this summer. Bionyra are a Sofinnova-incubated I&I biotech advancing in-licensed monoclonal (TL1A & IL25) & bispecific (TL1AxIL-23p19) HLE antibodies for a range of autoimmune indications. In this conversation we chat why, after a decade within Sanofi’s […]
Read MoreMore Tag
Backed by $165M, Bionyra Pharma Launches to Advance Inflammatory Disease Biologics
Though he is trained as a gastroenterologist and scientist, Frédéric Marrache, MD, PhD, has always had something of an entrepreneurial itch. Following his post-doctoral program and a stint in management consulting, he made his way to Sanofi where he would work on early- to mid-stage drug development programs focused on immune-mediated diseases. “This was right […]
Read MoreMore Tag
French Tech : Bionyra cible des maladies inflammatoires
Frédéric Marrache, cofondateur et PDG de Bionyra, était l’invité de Laure Closier dans French Tech, ce mercredi 24 juin. Il est revenu sur la levée de fonds 143 millions d’euros et le traitement des maladies inflammatoires par les biothérapies innovantes, dans Good Morning Business. Retrouvez l’émission du lundi au vendredi et réécoutez la en podcast. […]
Read MoreMore Tag
Bionyra launches with $165m, France’s largest biotech Series A
With an unusually strong fundraising trajectory, Paris-based Bionyra Pharma emerged from stealth today with financing that marks the largest life sciences biopharma Series A round in Europe this year and the largest of all time in France. The company develops next-generation biologics for immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and atopic dermatitis. The […]
Read MoreMore Tag
Bionyra’s $165M launch: A Sanofi alum, I&I candidates from China, one big catch-up
A former Sanofi I&I development executive has brought together a who’s who of investors and assembled three drug candidates from Chinese and US biotechs after scanning about 100 global assets. Frédéric Marrache, who spent much of the past decade at the French pharma leading clinical work on immunology and inflammation, has collected $165 million as […]
Read MoreMore Tag
Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets
For Bionyra Pharma co-founder and CEO Frédéric Marrache, M.D., Ph.D., “the planets had to align” to pull him out of his R&D VP role at Sanofi. But after weighing the opportunity to lead immunology and inflammation (I&I) biotech, he decided to take the jump and scratch the entrepreneurial itch he had been feeling for years. […]
Read MoreMore Tag